A review of real-world data on the effects of aripiprazole on weight and metabolic outcomes in adults

References

• American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27:596-601
   Google Scholar
• Citrome L, Jaffe A, Levine J, Martello D. Incidence, prevalence, and surveillance for diabetes in New York State psychiatric hospitals, 1997–2004. Psychiatr Serv 2006;57:1132-9
   PubMed Web of Science ®Google Scholar
• Newcomer JW. Comparing the safety and efficacy of atypical antipsychotics in psychiatric patients with comorbid medical illnesses. J Clin Psychiatry 2009;70(Suppl 3):30-6
   PubMed Web of Science ®Google Scholar
• Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005;19(Suppl 1):1-93
   PubMed Web of Science ®Google Scholar
• Citrome L, Blonde L, Damatarca C. Metabolic issues in patients with severe mental illness. South Med J 2005;98:714-20
   PubMed Web of Science ®Google Scholar
• Stroup TS, McEvoy JP, Ring KD, et al. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). Am J Psychiatry 2011;168:947-56
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-23
   PubMed Web of Science ®Google Scholar
• Nasrallah HA. Metabolic findings from the CATIE trial and their relation to tolerability. CNS Spectr 2006;11(7 Suppl 7):32-9
   PubMed Web of Science ®Google Scholar
• Narasimhan M, Masand P. Metabolic syndrome in patients with schizophrenia: CATIE results. Curr Psychiatry Rep 2006;8:213-4
   PubMedGoogle Scholar
• Citrome L. A review of aripiprazole in the treatment of patients with schizophrenia or bipolar I disorder. Neuropsychiatr Dis Treat 2006;2:427-43
   PubMedGoogle Scholar
• Citrome LL, Holt RI, Zachry WM, et al. Risk of treatment-emergent diabetes mellitus in patients receiving antipsychotics. Ann Pharmacother 2007;41:1593-603
   PubMed Web of Science ®Google Scholar
• Spurling RD, Lamberti JS, Olsen D, et al. Changes in metabolic parameters with switching to aripiprazole from another second-generation antipsychotic: a retrospective chart review. J Clin Psychiatry 2007;68:406-9
   PubMed Web of Science ®Google Scholar
• De Hert M, Hanssens L, van Winkel R, et al. A case series: evaluation of the metabolic safety of aripiprazole. Schizophr Bull 2007;33:823-30
   PubMed Web of Science ®Google Scholar
• van Winkel R, De Hert M, Wampers M, et al. Major changes in glucose metabolism, including new-onset diabetes, within 3 months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2008;69:472-9
   PubMed Web of Science ®Google Scholar
• Lee SY, Park MH, Patkar AA, Pae CU. A retrospective comparison of BMI changes and the potential risk factors among schizophrenic inpatients treated with aripiprazole, olanzapine, quetiapine or risperidone. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:490-6
   PubMed Web of Science ®Google Scholar
• Guo Z, L’italien GJ, Jing Y, et al. A real-world data analysis of dose effect of second-generation antipsychotic therapy on hemoglobin A1C level. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:1326-32
   PubMed Web of Science ®Google Scholar
• Guo X, Fang M, Zhai J, et al. Effectiveness of maintenance treatments with atypical and typical antipsychotics in stable schizophrenia with early stage: 1-year naturalistic study. Psychopharmacology (Berl) 2011;216:475-84
   PubMed Web of Science ®Google Scholar
• Nielsen J, Skadhede S, Correll CU. Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naïve schizophrenia patients. Neuropsychopharmacology 2010;35:1997-2004
   PubMed Web of Science ®Google Scholar
• Baker RA, Pikalov A, Tran QV, et al. Atypical antipsychotic drugs and diabetes mellitus in the US Food and Drug Administration Adverse Event database: a systematic Bayesian signal detection analysis. Psychopharmacol Bull 2009;42:11-31
   PubMed Web of Science ®Google Scholar
• Brixner DI, Said Q, Corey-Lisle PK, et al. Naturalistic impact of second-generation antipsychotics on weight gain. Ann Pharmacother 2006;40:626-32
   PubMed Web of Science ®Google Scholar
• Olfson M, Marcus SC, Corey-Lisle P, et al. Hyperlipidemia following treatment with antipsychotic medications. Am J Psychiatry 2006;163:1821-5
   PubMed Web of Science ®Google Scholar
• Yood MU, DeLorenze G, Quesenberry CP Jr, et al. The incidence of diabetes in atypical antipsychotic users differs according to agent – results from a multisite epidemiologic study. Pharmacoepidemiol Drug Saf 2009;18:791-9
   PubMed Web of Science ®Google Scholar
• DuMouchel W, Fram D, Yang X, et al. Antipsychotics, glycemic disorders, and life-threatening diabetic events: a Bayesian data-mining analysis of the FDA adverse event reporting system (1968–2004). Ann Clin Psychiatry 2008;20:21-31
   PubMed Web of Science ®Google Scholar
• Kessing LV, Thomsen AF, Mogensen UB, et al. Treatment with antipsychotics and the risk of diabetes in clinical practice. Br J Psychiatry 2010;197:266-71
   PubMed Web of Science ®Google Scholar
• Kim SH, Ivanova O, Abbasi FA, et al. Metabolic impact of switching antipsychotic therapy to aripiprazole after weight gain: a pilot study. J Clin Psychopharmacol 2007;27:365-8
   PubMed Web of Science ®Google Scholar
• Lee HY, Ham BJ, Kang RH, et al. Trial of aripiprazole in the treatment of first-episode schizophrenia. Psychiatry Clin Neurosci 2010;64:38-43
   PubMed Web of Science ®Google Scholar
• Takeuchi H, Uchida H, Suzuki T, et al. Changes in metabolic parameters following a switch to aripiprazole in Japanese patients with schizophrenia: one-year follow-up study. Psychiatry Clin Neurosci 2010;64:104-6
   PubMed Web of Science ®Google Scholar
• Ganguli R, Brar J, Garbut R, et al. Changes in weight and other metabolic indicators in persons with schizophrenia following a switch to aripiprazole. Clin Schizophr Relat Psychoses 2011;5:75-9
   PubMedGoogle Scholar
• Takahashi H, Oshimo T, Ishigooka J. Efficacy and tolerability of aripiprazole in first-episode drug-naive patients with schizophrenia: an open-label trial. Clin Neuropharmacol 2009;32:149-50
   PubMed Web of Science ®Google Scholar
• Schorr SG, Slooff CJ, Postema R, et al. A 12-month follow-up study of treating overweight schizophrenic patients with aripiprazole. Acta Psychiatrica Scand 2008;118:246-50
   PubMed Web of Science ®Google Scholar
• Kim SH, Nikolics L, Abbasi F, et al. Relationship between body mass index and insulin resistance in patients treated with second generation antipsychotic agents. J Psychiatr Res 2010;44:493-8
   PubMed Web of Science ®Google Scholar
• Kim SW, Shin IS, Kim JM, et al. Effectiveness of switching to aripiprazole from atypical antipsychotics in patients with schizophrenia. Clin Neuropharmacol 2009;32:243-9
   PubMed Web of Science ®Google Scholar
• Kwon JS, Jang JH, Kang DH, et al. Long-term efficacy and safety of aripiprazole in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder: 26-week prospective study. Psychiatry Clin Neurosci 2009;63:73-81
   PubMed Web of Science ®Google Scholar
• Casey DE. Side effect profiles of new antipsychotic agents. J Clin Psychiatry 1996;57(Suppl 11):40-5; discussion 46-52
   PubMed Web of Science ®Google Scholar
• Ulcickas Yood M, Delorenze GN, Quesenberry CP Jr, et al. Association between second-generation antipsychotics and newly diagnosed treated diabetes mellitus: does the effect differ by dose? BMC Psychiatry 2011;11:197
   PubMed Web of Science ®Google Scholar
• De Hert M, Yu W, Detraux J, et al. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder a systematic review and exploratory meta-analysis. CNS Drugs 2012;26:733-59
   PubMed Web of Science ®Google Scholar
• Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013;382:951-62
   PubMed Web of Science ®Google Scholar
• Morrato EH, Druss B, Hartung DM, et al. Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs. Arch Gen Psychiatry 2010;67:17-24
   PubMed Web of Science ®Google Scholar
• Morrato EH, Newcomer JW, Kamat S, et al. Metabolic screening after the American Diabetes Association’s consensus statement on antipsychotic drugs and diabetes. Diabetes Care 2009;32:1037-42
   PubMed Web of Science ®Google Scholar
• Berkowitz RL, Patel U, Ni Q, et al. The impact of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) on prescribing practices: an analysis of data from a large midwestern state. J Clin Psychiatry 2012;73:498-503
   PubMed Web of Science ®Google Scholar
• Essock SM, Covell NH, Davis SM, et al. Effectiveness of switching antipsychotic medications. Am J Psychiatry 2006;163:2090-5
   PubMed Web of Science ®Google Scholar
• Weiden PJ. Switching antipsychotic medications: not enough, too often, or just right? Am J Psychiatry 2011;168:882-4
   PubMed Web of Science ®Google Scholar
• Hasan A, Falkai P, Wobrock T, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry 2013;14:2-44
   Google Scholar
• Simon V, van Winkel R, De Hert M. Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review. J Clin Psychiatry 2009;70:1041-50
   PubMed Web of Science ®Google Scholar
• Rummel-Kluge C, Komossa K, Schwarz S, et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res 2010;123:225-33
   PubMed Web of Science ®Google Scholar